Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-TREC
NCT02945566Phase 3Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Jun 2017
- Primary completion
- Aug 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of capecitabine in rectal cancer (3 arms), sponsored by University of Birmingham. Primary endpoints: Recruitment Rate at 24 months and Organ Preservation at 30 months. Started Jun 2017; status: active, not recruiting.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02945566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945566.